1
|
Chatterjee K, De S, Deb Roy S, Sahu SK, Chakraborty A, Ghatak S, Das N, Mal S, Roy Chattopadhyay N, Das P, Reddy RR, Mukherjee S, Das AK, Puii Z, Zomawia E, Singh YI, Tsering S, Riba K, Rajasubramaniam S, Suryawanshi AR, Choudhuri T. BAX -248 G>A and BCL2 -938 C>A Variant Lowers the Survival in Patients with Nasopharyngeal Carcinoma and Could be Associated with Tissue-Specific Malignancies: A Multi-Method Approach. Asian Pac J Cancer Prev 2021; 22:1171-1181. [PMID: 33906310 PMCID: PMC8325122 DOI: 10.31557/apjcp.2021.22.4.1171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Indexed: 11/25/2022] Open
Abstract
Background: The association of BAX -248 G>A and BCL2 -938 C>A with different cancers created conflicts. We studied the correlation and the effect of these polymorphisms in patients with Nasopharyngeal Carcinoma (NPC). Methods: PCR-RFLP and Sanger sequencing were used to detect polymorphisms. Statistical analysis including forest plot and Kaplan-Meier Log-rank test was conducted to investigate the association and effect of these SNPs on the NPC patients’ survival. The computational study was performed to investigate the possible regulatory role between these polymorphisms and the poor survival of NPC patients. Meta-analysis was executed to check the tissue-specific association of these polymorphisms in the context of global cancer prognosis. Results: We observed an increased and significant association of BAX -248 G>A [GA:OR=5.29, 95%CI=1.67,16.67, P=0.004; GA+AA:OR=5.71, 95%CI=1.82,17.90, P =0.002; A:OR=5.33, 95%CI=1.76,16.13, P=0.003], and BCL2 -938 C>A [CA:OR=2.26, 95%CI=1.03,4.96, P=0.04; AA:OR=3.56, 95%CI=0.97,13.05, P=0.05; CA+AA:OR=3.10, 95%CI=1.51,6.35, P=0.002; A:OR=2.90, 95% CI=1.59,5.29, P=0.0005] with the risk of NPC. Also, these SNPs were strongly correlated with poor survival in NPC patients (lower estimated survival mean, lower estimated proportion surviving at 5 years with p<0.05). The computational study showed that these SNPs altered the binding affinity of transcription factors HIF1, SP1, PAX3, PAX9 and CREB towards promoter (Lower p indicates strong affinity). The meta-analysis revealed the tissue-specific association of these polymorphisms. BAX -248 G>A showed a significant correlation with carcinomas [A vs G:OR=1.60, 95%CI=1.09,2.34, P=0.01; AA vs GG:OR=2.61, 95%CI=1.68,4.06, P<0.001; AA+GA vs GG:OR=1.53,95%CI=1.04,2.25, P=0.02); AA vs GG+GA:OR=2.53, 95%CI=1.65,3.87, P<0.001], and BCL2 -938 C>A with other malignancies [A vs C:OR=1.45, 95%CI=1.26,1.66, P<0.001; AA vs CC:OR=2.07, 95%CI: 1.15,3.72, P=0.01; AA+CA vs CC:OR=1.42, 95%CI=1.18,1.72, P<0.001; AA vs CC+CA:OR=1.89, 95%CI=1.02,3.50, P=0.04]. Conclusions: BAX -248 G>A and BCL2 -938 C>A was associated with poor survival in NPC patients. It may increase cancer susceptibility through transcriptional regulation. Moreover, these SNPs’ effects could be tissue-specific.
Collapse
Affiliation(s)
- Koustav Chatterjee
- Department of Biotechnology, Visva-Bharati, Santiniketan, Birbhum, West Bengal, India
| | - Saikat De
- Department of Biotechnology, Visva-Bharati, Santiniketan, Birbhum, West Bengal, India
| | - Sankar Deb Roy
- Department of Radiation Oncology, Eden Medical Centre, Dimapur, Nagaland, India
| | - Sushil Kumar Sahu
- Department of Pharmacology and Molecular Sciences, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States
| | | | - Sandeep Ghatak
- Division of Animal and Fishery Science, ICAR Research Complex for North East Hill Region,Umiam, Meghalaya, India
| | - Nilanjana Das
- Department of Biotechnology, Visva-Bharati, Santiniketan, Birbhum, West Bengal, India
| | - Sudipa Mal
- Department of Biotechnology, Visva-Bharati, Santiniketan, Birbhum, West Bengal, India
| | | | - Piyanki Das
- Department of Biotechnology, Visva-Bharati, Santiniketan, Birbhum, West Bengal, India
| | - R Rajendra Reddy
- Clinical Proteomics, Institute of Life Sciences, Bhubaneswar, India
| | - Syamantak Mukherjee
- Department of Biotechnology, Visva-Bharati, Santiniketan, Birbhum, West Bengal, India
| | - Ashok Kumar Das
- Department of ENT, Dr B. Borooah Cancer Institute, Guwahati, Assam, India
| | - Zoreng Puii
- State Referral Hospital, Falkawn, Mizoram, India
| | - Eric Zomawia
- State Referral Hospital, Falkawn, Mizoram, India
| | - Yengkhom Indibor Singh
- Regional Institute of Medical Sciences, Department of Radiotherapy, Imphal, Manipur, India
| | - Sam Tsering
- Tertiary cancer center,TomoRiba Institute of Health And Medical Sciences, Arunachal Pradesh, India
| | - Komri Riba
- Tertiary cancer center,TomoRiba Institute of Health And Medical Sciences, Arunachal Pradesh, India
| | - Shanmugam Rajasubramaniam
- Division of Genetic Disorders ICMR-National Institute of Research in Tribal Health, NIRTH Complex, Jabalpur, Madhya Pradesh, India
| | | | - Tathagata Choudhuri
- Department of Biotechnology, Visva-Bharati, Santiniketan, Birbhum, West Bengal, India
| |
Collapse
|
2
|
Yu A, Zhao L, Kang Q, Li J, Chen K, Fu H. Transcription factor HIF1α promotes proliferation, migration, and invasion of cholangiocarcinoma via long noncoding RNA H19/microRNA-612/Bcl-2 axis. Transl Res 2020; 224:26-39. [PMID: 32505707 DOI: 10.1016/j.trsl.2020.05.010] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2020] [Revised: 05/25/2020] [Accepted: 05/28/2020] [Indexed: 12/20/2022]
Abstract
Cholangiocarcinoma, which is the most common invasive malignant tumor of the biliary tract, has poor prognosis. There is evidence suggesting that hypoxia-inducible factor 1α (HIF1α) plays an important role in cholangiocarcinoma. Also, microRNA-612 (miR-612) is another key regulator of cholangiocarcinoma. In this study, we investigate the scantly documented interaction of HIF1α and miR-612 in cholangiocarcinoma. We first undertook microarray-based cholangiocarcinoma gene expression profiles to screen out the differentially expressed long noncoding RNAs (lncRNAs) and genes. We used reverse transcription quantitative polymerase chain reaction to detect the expression of HIF1α in normal bile duct and cholangiocarcinoma tissues, and in corresponding cells lines. Cell counting kit 8, scratch, and Transwell assays were used to detect the proliferation, migration and invasion of cholangiocarcinoma cells. Cell cycle distribution and apoptosis were detected by flow cytometry. ChIP, dual luciferase reporter gene assay, RNA pull-down, and RNA immunoprecipitation were used to verify relationship between HIF1α and lncRNA H19, and lncRNA H19 and miR-612. We also monitored tumor formation in nude mice to verify the effect of HIF1α on cholangiocarcinoma. HIF1α expression was elevated in cholangiocarcinoma tissues and cells. Silencing HIF1α reduced proliferation, migration, and invasion of cholangiocarcinoma cells. HIF1α transcriptionally activated the expression of lncRNA H19. Overexpression of miR-612 could rescue the proliferation, migration and invasion of cholangiocarcinoma cells caused by lncRNA H19 overexpression. Taken together, HIF1α activated lncRNA H19-mediated miR-612/Bcl-2 pathway to promote cholangiocarcinoma, suggesting a promising therapeutic target for cholangiocarcinoma.
Collapse
Affiliation(s)
- Aijun Yu
- The First Department of General Surgery, Affiliated Hospital of Chengde Medical University, Chengde, P.R. China.
| | - Luwen Zhao
- The First Department of Gynecology, Affiliated Hospital of Chengde Medical University, Chengde, P.R. China
| | - Qingmin Kang
- The First Department of General Surgery, Affiliated Hospital of Chengde Medical University, Chengde, P.R. China
| | - Jian Li
- The First Department of General Surgery, Affiliated Hospital of Chengde Medical University, Chengde, P.R. China
| | - Kai Chen
- The First Department of General Surgery, Affiliated Hospital of Chengde Medical University, Chengde, P.R. China
| | - Hua Fu
- The First Department of General Surgery, Affiliated Hospital of Chengde Medical University, Chengde, P.R. China
| |
Collapse
|
3
|
Ma X, Liang AL, Liu YJ. Research progress on the relationship between lung cancer drug-resistance and microRNAs. J Cancer 2019; 10:6865-6875. [PMID: 31839821 PMCID: PMC6909942 DOI: 10.7150/jca.31952] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2018] [Accepted: 09/13/2019] [Indexed: 02/07/2023] Open
Abstract
Lung cancer, a malignant tumor with the highest death rate of cancer, seriously endangers human health. And its pathogenesis and mechanism of drug resistance has been partially clarified, especially for the signal pathway of epidermal growth factor receptor (EGFR). The targeting therapy of EGFR signaling pathway in non-small cell lung cancer (NSCLC) has achieved a certain effect, but the two mutation of EGFR and other mechanisms of lung cancer resistance still greatly reduce the therapeutic effect of chemotherapy on it. MicroRNA is an endogenous non coding RNA, which has a regulatory function after transcriptional level. Recent studies on the mechanism of lung cancer resistance have found that a variety of microRNAs are related to the mechanism of lung cancer drug-resistance. They can regulate lung cancer resistance by participating in signal pathways, drug resistance genes and cell apoptosis, thus affecting the sensitivity of cancer cells to drugs. Therefore, microRNAs can be used as a specific target for the treatment of lung cancer and plays a vital role in the early diagnosis, prognosis and treatment of lung cancer. This article reviews the mechanisms of lung cancer resistance and its relationship with microRNAs.
Collapse
Affiliation(s)
- Xuan Ma
- Medical Molecular Diagnostics Key Laboratory of Guangdong & Departments of Biochemistry and Molecular Biology & Departments of Clinical Biochemistry, Guangdong Medical University, 523808, Dongguan, Guangdong, P.R. China
| | - Ai-Ling Liang
- Medical Molecular Diagnostics Key Laboratory of Guangdong & Departments of Biochemistry and Molecular Biology & Departments of Clinical Biochemistry, Guangdong Medical University, 523808, Dongguan, Guangdong, P.R. China
| | - Yong-Jun Liu
- Medical Molecular Diagnostics Key Laboratory of Guangdong & Departments of Biochemistry and Molecular Biology & Departments of Clinical Biochemistry, Guangdong Medical University, 523808, Dongguan, Guangdong, P.R. China
| |
Collapse
|
4
|
Jin C, Song P, Pang J. The CK2 inhibitor CX4945 reverses cisplatin resistance in the A549/DDP human lung adenocarcinoma cell line. Oncol Lett 2019; 18:3845-3856. [PMID: 31579410 DOI: 10.3892/ol.2019.10696] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2018] [Accepted: 06/13/2019] [Indexed: 12/31/2022] Open
Abstract
Lung cancer negatively impacts global health, and the incidence of non-small cell lung cancer (NSCLC) is highest among all forms of lung cancer. Chemotherapy failure mainly occurs due to drug resistance; however, the associated molecular mechanism remains unclear. Casein kinase II (CK2), which plays important roles in the occurrence, development and metastasis of many tumours, regulates Wnt signaling by modulating β-catenin expression. In the present study the effects of the CK2 inhibitor, CX4945 on cisplatin [or cis-diamminedichloroplatinum (II); (DDP)]-resistant A549 cells (A549/DDP) were investigated to elucidate the underlying molecular mechanism. A549/DDP cells were divided into four groups (blank control, CX4945, cisplatin and CX4945+cisplatin). Cisplatin resistance was 5.16-fold greater in A549/DDP cells compared with that in A549 cells, with an optimal cisplatin concentration of 5 µg/ml. Moreover, levels of CK2, dishevelled-2 (DVL-2) phosphorylated (p) at Ser143 (p-DVL-2Ser143), and major Wnt-signaling proteins were significantly higher in A549/DDP cells compared with that in A549 cells (P<0.05), with these levels further increased following cisplatin treatment (P<0.05), whereas these levels significantly decreased in A549 cells after cisplatin treatment (P<0.05). Additionally, multidrug-resistance-associated protein 1 and lung resistance protein expression was significantly higher in A549/DDP cells compared with that in A549 cells (P<0.05), with these levels increasing further in A549/DDP (P<0.05) but not A549 cells upon cisplatin treatment (P>0.05). In addition, reduced expression of resistance proteins in A549/DDP cells was accompanied by a decline in the 50% growth inhibition after CX4945 pre-treatment. Furthermore, levels of p-DVL-2Ser143 and major Wnt-signaling proteins decreased significantly after treatment of A549/DDP cells with CX4945+cisplatin, whereas DVL-2 and p-DVL-2Thr224 levels remained unchanged. Additionally, significant elevations in apoptosis rates in the CX4945+cisplatin group relative to the control and cisplatin-only groups, was observed (P<0.001). These results suggested that inhibiting Wnt/β-catenin signaling with CX4945, which attenuates levels of drug-resistance-associated proteins and induces apoptosis, might reverse cisplatin resistance in NSCLC.
Collapse
Affiliation(s)
- Chengji Jin
- Respiratory Department, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China
| | - Ping Song
- Respiratory Department, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China
| | - Ji Pang
- Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China
| |
Collapse
|
5
|
Peddireddy V, Badabagni SP, Gundimeda SD, Mundluru HP. Association of eNOS
and ACE
gene polymorphisms and plasma nitric oxide with risk of non-small cell lung cancer in South India. CLINICAL RESPIRATORY JOURNAL 2016; 12:207-217. [DOI: 10.1111/crj.12517] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/08/2015] [Revised: 06/14/2016] [Accepted: 06/17/2016] [Indexed: 12/27/2022]
Affiliation(s)
- Vidyullatha Peddireddy
- Department of Environmental Toxicology, Institute of Genetics and Hospital for Genetic Diseases, Osmania University; Hyderabad India
- Present address: Department of Biotechnology; University of Hyderabad; Hyderabad Andhra Pradesh 500046 India
| | - Siva Prasad Badabagni
- Department of Environmental Toxicology, Institute of Genetics and Hospital for Genetic Diseases, Osmania University; Hyderabad India
| | - Sandhya Devi Gundimeda
- Department of Biotechnology, School of Life Sciences, University of Hyderabad, Indo-American Cancer Hospital; Hyderabad India
| | - Hema Prasad Mundluru
- Department of Environmental Toxicology, Institute of Genetics and Hospital for Genetic Diseases, Osmania University; Hyderabad India
| |
Collapse
|
6
|
Stelmach P, Wedemeyer C, Fuest L, Kurscheid G, Gehrke T, Klenke S, Jäger M, Kauther MD, Bachmann HS. The BCL2 -938C>A Promoter Polymorphism Is Associated with Risk for and Time to Aseptic Loosening of Total Hip Arthroplasty. PLoS One 2016; 11:e0149528. [PMID: 26881923 PMCID: PMC4755546 DOI: 10.1371/journal.pone.0149528] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2015] [Accepted: 02/02/2016] [Indexed: 01/15/2023] Open
Abstract
Aseptic loosening is a major cause of revision surgery of total hip arthroplasty (THA). Only few host factors affecting aseptic loosening have been identified until now, although they are urgently needed to identify and possibly treat those patients at higher risk for aseptic loosening. To determine whether the functional single nucleotide polymorphism (SNP) c.-938C>A (rs2279115), located in the promoter region of the BCL2 gene has an impact on aseptic loosening of THA we genotyped and analyzed 234 patients suffering from aseptic loosening and 231 patients after primary THA. The polymorphism is associated with risk for aseptic loosening with the CC genotype at highest risk for aseptic loosening, Odds Ratio CC vs. AA 1.93, 95%CI 1.15-3.25, p = 0.013. In contrast, low risk AA genotype carriers that still developed aseptic loosening showed a significantly shorter time to aseptic loosening than patients carrying the C allele (p = 0.004). These results indicate that the BCL2 -938C>A polymorphism influences the occurrence and course of aseptic loosening and suggests this polymorphism as an interesting candidate for prospective studies and analyses in THA registers.
Collapse
Affiliation(s)
- Patrick Stelmach
- Institute of Pharmacogenetics, University Hospital Essen, Essen, Germany
| | - Christian Wedemeyer
- Department of Orthopaedics and Trauma Surgery, University Hospital Essen, Essen, Germany
| | - Lena Fuest
- Institute of Pharmacogenetics, University Hospital Essen, Essen, Germany
- Department of Orthopaedics and Trauma Surgery, University Hospital Essen, Essen, Germany
| | - Gina Kurscheid
- Institute of Pharmacogenetics, University Hospital Essen, Essen, Germany
- Department of Orthopaedics and Trauma Surgery, University Hospital Essen, Essen, Germany
| | - Thorsten Gehrke
- Department of Joint Surgery, Helios ENDO-Klinik, Hamburg, Germany
| | - Stefanie Klenke
- Institute of Pharmacogenetics, University Hospital Essen, Essen, Germany
- Department of Anaesthesiology and Intensive Care, University Hospital Essen, Essen, Germany
| | - Marcus Jäger
- Department of Orthopaedics and Trauma Surgery, University Hospital Essen, Essen, Germany
| | - Max D. Kauther
- Department of Orthopaedics and Trauma Surgery, University Hospital Essen, Essen, Germany
| | - Hagen S. Bachmann
- Institute of Pharmacogenetics, University Hospital Essen, Essen, Germany
- * E-mail:
| |
Collapse
|